Literature DB >> 28507073

Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Shawn M Zimmerman1, Jeremy S Dyke1, Tomislav P Jelesijevic1,2, Frank Michel2, Eric R Lafontaine1, Robert J Hogan3,2.   

Abstract

Burkholderia mallei, a facultative intracellular bacterium and tier 1 biothreat, causes the fatal zoonotic disease glanders. The organism possesses multiple genes encoding autotransporter proteins, which represent important virulence factors and targets for developing countermeasures in pathogenic Gram-negative bacteria. In the present study, we investigated one of these autotransporters, BatA, and demonstrate that it displays lipolytic activity, aids in intracellular survival, is expressed in vivo, elicits production of antibodies during infection, and contributes to pathogenicity in a mouse aerosol challenge model. A mutation in the batA gene of wild-type strain ATCC 23344 was found to be particularly attenuating, as BALB/c mice infected with the equivalent of 80 median lethal doses cleared the organism. This finding prompted us to test the hypothesis that vaccination with the batA mutant strain elicits protective immunity against subsequent infection with wild-type bacteria. We discovered that not only does vaccination provide high levels of protection against lethal aerosol challenge with B. mallei ATCC 23344, it also protects against infection with multiple isolates of the closely related organism and causative agent of melioidosis, Burkholderia pseudomallei Passive-transfer experiments also revealed that the protective immunity afforded by vaccination with the batA mutant strain is predominantly mediated by IgG antibodies binding to antigens expressed exclusively in vivo Collectively, our data demonstrate that BatA is a target for developing medical countermeasures and that vaccination with a mutant lacking expression of the protein provides a platform to gain insights regarding mechanisms of protective immunity against B. mallei and B. pseudomallei, including antigen discovery.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  aerosols; autotransporter proteins; biodefense; countermeasures; glanders; immunoprotective antibodies; melioidosis; virulence determinants

Mesh:

Substances:

Year:  2017        PMID: 28507073      PMCID: PMC5520430          DOI: 10.1128/IAI.00102-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  137 in total

1.  Type VI secretion is a major virulence determinant in Burkholderia mallei.

Authors:  Mark A Schell; Ricky L Ulrich; Wilson J Ribot; Ernst E Brueggemann; Harry B Hines; Dan Chen; Lyla Lipscomb; H Stanley Kim; Jan Mrázek; William C Nierman; David Deshazer
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

2.  Identification and molecular analysis of the gene encoding Rickettsia typhi hemolysin.

Authors:  S Radulovic; J M Troyer; M S Beier; A O Lau; A F Azad
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

4.  Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.

Authors:  Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

5.  The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei.

Authors:  Mary N Burtnick; Paul J Brett; Sarah V Harding; Sarah A Ngugi; Wilson J Ribot; Narisara Chantratita; Angelo Scorpio; Timothy S Milne; Rachel E Dean; David L Fritz; Sharon J Peacock; Joanne L Prior; Timothy P Atkins; David Deshazer
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

6.  The C-terminal fragment of the internal 110-kilodalton passenger domain of the Hap protein of nontypeable Haemophilus influenzae is a potential vaccine candidate.

Authors:  Dai-Fang Liu; Kathryn W Mason; Maria Mastri; Mehran Pazirandeh; David Cutter; Doran L Fink; Joseph W St Geme; Duzhang Zhu; Bruce A Green
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  The autotransporter esterase EstA of Pseudomonas aeruginosa is required for rhamnolipid production, cell motility, and biofilm formation.

Authors:  Susanne Wilhelm; Aneta Gdynia; Petra Tielen; Frank Rosenau; Karl-Erich Jaeger
Journal:  J Bacteriol       Date:  2007-07-13       Impact factor: 3.490

8.  Type 3 secretion system cluster 3 is a critical virulence determinant for lung-specific melioidosis.

Authors:  Maria G Gutierrez; Tia L Pfeffer; Jonathan M Warawa
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

9.  Novel targets of the CbrAB/Crc carbon catabolite control system revealed by transcript abundance in Pseudomonas aeruginosa.

Authors:  Elisabeth Sonnleitner; Martina Valentini; Nicolas Wenner; Feth el Zahar Haichar; Dieter Haas; Karine Lapouge
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.

Authors:  Rebecca Lipsitz; Susan Garges; Rosemarie Aurigemma; Prasith Baccam; David D Blaney; Allen C Cheng; Bart J Currie; David Dance; Jay E Gee; Joseph Larsen; Direk Limmathurotsakul; Meredith G Morrow; Robert Norton; Elizabeth O'Mara; Sharon J Peacock; Nicki Pesik; L Paige Rogers; Herbert P Schweizer; Ivo Steinmetz; Gladys Tan; Patrick Tan; W Joost Wiersinga; Vanaporn Wuthiekanun; Theresa L Smith
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

View more
  9 in total

Review 1.  Emerging role of biologics for the treatment of melioidosis and glanders.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  Expert Opin Biol Ther       Date:  2019-10-15       Impact factor: 4.388

2.  A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates.

Authors:  Sarah M Baker; Christopher J H Davitt; Natalya Motyka; Nicole L Kikendall; Kasi Russell-Lodrigue; Chad J Roy; Lisa A Morici
Journal:  Vaccines (Basel)       Date:  2017-12-09

3.  The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Eric R Lafontaine; Zhenhai Chen; Maria Cristina Huertas-Diaz; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Robert J Hogan; Biao He
Journal:  Vaccine X       Date:  2018-12-22

4.  Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis.

Authors:  Nittaya Khakhum; Preeti Bharaj; Julia N Myers; Daniel Tapia; David H Walker; Janice J Endsley; Alfredo G Torres
Journal:  PLoS Negl Trop Dis       Date:  2019-07-15

Review 5.  Current Advances in Burkholderia Vaccines Development.

Authors:  Guanbo Wang; Paulina Zarodkiewicz; Miguel A Valvano
Journal:  Cells       Date:  2020-12-11       Impact factor: 6.600

6.  Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.

Authors:  Nittaya Khakhum; Preeti Bharaj; David H Walker; Alfredo G Torres; Janice J Endsley
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

7.  Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp.

Authors:  Robert J Hogan; Eric R Lafontaine
Journal:  mSphere       Date:  2019-01-02       Impact factor: 4.389

8.  Transcriptome analysis of human monocytic cells infected with Burkholderia species and exploration of pentraxin-3 as part of the innate immune response against the organisms.

Authors:  Sophie A Aschenbroich; Eric R Lafontaine; Maria Cecilia Lopez; Henry V Baker; Robert J Hogan
Journal:  BMC Med Genomics       Date:  2019-09-06       Impact factor: 3.063

9.  The Peptidoglycan-associated lipoprotein Pal contributes to the virulence of Burkholderia mallei and provides protection against lethal aerosol challenge.

Authors:  Jeremy S Dyke; Maria Cristina Huertas-Diaz; Frank Michel; Nathan E Holladay; Robert J Hogan; Biao He; Eric R Lafontaine
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.